Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | FRMPD3 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.001 |
mRNA | MTA1 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | GADD45G | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | OGFOD2 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
mRNA | PXDC1 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
mRNA | TNS3 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
mRNA | NR2F1 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | GSTA4 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | KRT72 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.001 |
mRNA | RERE | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |